Combined Oral Contraceptives Containing 17β-Estradiol in the United States
Yes, combined oral contraceptives containing 17β-estradiol are available in the United States, but options are extremely limited compared to Europe.
Available Brand Names in the U.S.
The evidence provided does not identify specific U.S. brand names for 17β-estradiol-based combined oral contraceptives. However, based on the guideline recommendations and research evidence:
Formulations Mentioned in Guidelines:
International Context:
The 2012 French guidelines 2 mention that Zoely® (containing 17β-estradiol 1.5 mg) was released in late 2011 in Europe. Research evidence 3, 4 discusses nomegestrol acetate/estradiol combinations launched in Europe in 2011, but these studies do not confirm U.S. availability.
Important Clinical Considerations
Why 17β-Estradiol Formulations Matter:
The 2021 Blood Reviews guidelines 1 specifically recommend 17β-estradiol-based COCs as first-choice contraception when contraception is required, particularly for:
- Young women with premature ovarian insufficiency
- Cancer survivors at increased cardiovascular risk
- Patients requiring better metabolic and cardiovascular safety profiles
The rationale: 17β-estradiol avoids the "first-line hepatic effect" of ethinyl estradiol, demonstrates better bone mass accrual profiles, and may reduce cardiovascular and thrombotic risks 1.
U.S. Availability Gap:
While oral 17β-estradiol tablets are FDA-approved and available in the U.S. 5 for hormone replacement therapy (in 0.5 mg, 1 mg, and 2 mg doses), the evidence does not confirm FDA-approved combined oral contraceptive formulations containing 17β-estradiol with progestins specifically marketed for contraception in the United States.
Alternative Approaches in the U.S.:
If 17β-estradiol-based COCs are not available or accessible:
Transdermal 17β-estradiol patches (widely available in the U.S.) combined with oral progestins can be used as an alternative approach 1
- Patches releasing 50 μg of 17β-estradiol daily
- Add micronized progesterone 200 mg daily for 12-14 days every 28 days
Traditional ethinyl estradiol-based COCs remain the standard second-choice option 1
Clinical Caveat:
The regulatory landscape differs significantly between Europe and the United States. European formulations containing 17β-estradiol combined with nomegestrol acetate or dienogest may not have undergone FDA approval processes. Clinicians should verify current FDA-approved formulations directly with pharmaceutical databases or the FDA website, as the evidence provided does not establish definitive U.S. market availability of these specific combined oral contraceptive formulations.